Announcement • Jul 27
Genvor Antimicrobial Peptides Advance into Sugar Beet Research Genvor Inc. announced that its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, storage, and processing. The research is being conducted under the ARS Sustainable Sugar Beet Research Initiative, with Genvor serving as a collaborator contributing its antimicrobial peptides for evaluation. The project focuses on the development and evaluation of antimicrobial peptide technologies for agriculture, with the goal of advancing peptide-based approaches to crop protection, including work aimed at improving crop resilience and reducing microbial threats in major agricultural systems. The sugar beet project extends that work into an additional high-value crop sector. Microbial activity during storage and processing can reduce sugar recovery, product quality, and operational efficiency. Through this collaboration, USDA-ARS researchers will evaluate whether Genvor’s antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction, with the goal of supporting more efficient and sustainable sugar beet production. The collaboration is expected to generate research data that may inform future peptide-based strategies for crop protection, post-harvest quality, and processing efficiency. Announcement • May 23
Genvor Incorporated Appoints Donald Kalkofen as Chief Financial Officer Genvor Incorporated announced the appointment of Donald Kalkofen as Chief Financial Officer. In this role, Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health and wellness. Mr. Kalkofen brings more than 20 years of Chief Financial Officer experience leading finance and operations across biotechnology, financial services, and technology, with a proven track record of guiding companies through initial public offerings and complex capital markets transactions. Most recently, he served as Chief Financial Officer of Alpha Cognition Inc., a publicly traded CNS-focused biotechnology company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s, where he led the preparations for the company’s successful NASDAQ listing and helped to establish new banking, audit committee, and investor relations functions. Prior to Alpha Cognition, Mr. Kalkofen served as Chief Financial Officer of Protagonist Therapeutics, a publicly traded clinical-stage biopharmaceutical company, where he helped guide the company’s strong growth and supported the company’s successful SOX 404(b) implementation. Earlier in his career, Mr. Kalkofen held Chief Financial Officer and senior finance leadership roles at Symantec Corporation and West Coast Bancorp, where he took the bank public on NASDAQ and led growth from $90 million to $1.5 billion in assets. Mr. Kalkofen is a Certified Public Accountant (inactive) and holds a Bachelor of Arts in Accounting from Washington State University. Announcement • Feb 11
Genvor, Inc. Announces the Publication of Peer-Reviewed Research Validated Its Proprietary Agm182 Antifungal Peptide Technology in Phytofrontiers Genvor Inc. announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology in PhytoFrontiers™?, a journal of the American Phytopathological Society. The study, conducted in collaboration with the United States Department of Agriculture's Agricultural Research Service (USDA-ARS), demonstrates that transgenic corn expressing AGM182 achieves significant pre-harvest resistance to Aspergillus flavus and aflatoxin contamination. Aflatoxins are naturally occurring toxic and carcinogenic compounds produced by Aspergillus flavus that contain corn and other crops, posing significant risks to human and animal health. Economic losses fromungal diseases in corn are substantial, with total annual U.S. losses estimated between $3 billion and $5 billion. Aflatoxin contamination alone has potential annual market impacts ranging from approximately $52 million in lower-risk years to $1.68 billion in high-risk years. The peer-reviewed publication follows Genvor's November 2025 announcement that the USPTO issued U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, co-assigned with the USDA. Together, the patent and publication provide both intellectual property protection and independent scientific validation of the technology's commercial potential. The research was conducted at the USDA-ARS Food and Feed Safety Research Unit at the Southern Regional Research Center in New Orleans, Louisiana, in collaboration with scientists from Tuskegee University and Genvor. The study builds on Genvor's over 7-year Cooperative Research and Development Agreement (CRADA) with the USDA-ARS, which focuses on developing corn varieties resistant to pre-harvest aflatoxin contamination. 
